{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:35:09Z","timestamp":1787585709618,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babes\u201d University of Medicine and Pharmacy Timi\u0219oara"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Background: Paclitaxel is a cornerstone chemotherapeutic agent widely used in breast cancer treatment, primarily through the stabilization of microtubule dynamics. Beyond its canonical tubulin-targeting activity, increasing evidence suggests that paclitaxel may engage additional molecular targets, contributing to its complex pharmacological profile. In this study, an integrated computational workflow was applied to evaluate the structural compatibility between paclitaxel and the neurokinin-2 receptor (NK2R), a G protein-coupled receptor involved in tumor-associated inflammatory and proliferative signaling pathways. Physicochemical profiling and target prediction were performed using SwissADME and SwissTargetPrediction, followed by molecular docking and molecular dynamics simulations using AutoDock Vina and GROMACS 2024.1. Paclitaxel exhibited physicochemical properties consistent with transient interactions in hydrophobic transmembrane environments. Docking analysis identified a plausible binding mode within the NK2R transmembrane cavity, primarily stabilized by hydrophobic contacts. Molecular dynamics simulations over 100 ns revealed stable ligand occupancy and overall complex stability, while MM-PBSA calculations indicated a favorable transient association. The predicted interaction is consistent with secondary or non-canonical receptor engagement. While NK2R is not established as a pharmacological target of paclitaxel, the results support the structural feasibility of a previously uncharacterized receptor interaction and provide a reproducible computational framework for exploring GPCR-associated effects of cytotoxic agents.<\/jats:p>","DOI":"10.3390\/bioengineering13080953","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:20:36Z","timestamp":1787322036000},"page":"953","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel\u2013NK2R Interaction"],"prefix":"10.3390","volume":"13","author":[{"given":"Corina","family":"Duda-Seiman","sequence":"first","affiliation":[{"name":"Titu Maiorescu University, Vacaresti 187, 040051 Bucure\u0219ti, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3811","authenticated-orcid":false,"given":"Liliana Mititelu","family":"Tartau","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-7655","authenticated-orcid":false,"given":"Bogdan","family":"Hoinoiu","sequence":"additional","affiliation":[{"name":"Department of Oral Rehabilitation and Dental Emergencies, Faculty of Dentistry, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Interdisciplinary Research Center for Dental Medical Research, Lasers and Innovative Technologies, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3386-8468","authenticated-orcid":false,"given":"Daniel","family":"Pit","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Center for Advanced Research in Cardiovascular Pathology and Hemostaseology, 300041 Timisoara, Romania"},{"name":"Department I of Nursing, University Clinic of Clinical Skills, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Doina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Department of Professional Legislation in Dental Medicine, Faculty of Dental Medicine, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rusu","sequence":"additional","affiliation":[{"name":"Titu Maiorescu University, Vacaresti 187, 040051 Bucure\u0219ti, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Luca","sequence":"additional","affiliation":[{"name":"Titu Maiorescu University, Vacaresti 187, 040051 Bucure\u0219ti, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8621-0505","authenticated-orcid":false,"given":"Eliza Gratiela","family":"Popa","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-7621","authenticated-orcid":false,"given":"Teodora","family":"Hoinoiu","sequence":"additional","affiliation":[{"name":"Center for Advanced Research in Cardiovascular Pathology and Hemostaseology, 300041 Timisoara, Romania"},{"name":"Department I of Nursing, University Clinic of Clinical Skills, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/tbcr-25-26","article-title":"Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","volume":"6","author":"Venkataraman","year":"2025","journal-title":"Trans. Breast Cancer Res."},{"key":"ref_2","unstructured":"(2025, September 18). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(25)00136-6","article-title":"Projected global rise in breast cancer incidence and mortality by 2050","volume":"26","author":"Devi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41746-025-01967-7","article-title":"Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer","volume":"8","author":"Kuang","year":"2025","journal-title":"Npj Digit. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101288","DOI":"10.1016\/j.drup.2025.101288","article-title":"Drug resistance in breast cancer: Mechanisms and strategies for management","volume":"83","author":"Wu","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s12672-025-03420-3","article-title":"Emerging trends and global collaboration in Paclitaxel resistance research for breast cancer: A comprehensive bibliometric study","volume":"16","author":"Meng","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nevala, W.K., Geng, L., Xie, H., Stueven, N.A., and Markovic, S.N. (2025). PD-L1-targeting nanoparticles for the treatment of triple-negative breast cancer: A preclinical model. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26073295"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1038\/s41598-025-92805-z","article-title":"Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations","volume":"15","author":"Bozdaganyan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114036","DOI":"10.1016\/j.jconrel.2025.114036","article-title":"Advances in paclitaxel nanoformulations: A systematic review of in vivo therapeutic efficacy and safety enhancements","volume":"385","author":"Seyam","year":"2025","journal-title":"J. Control Release"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ji, Q., Zhu, H., Qin, Y., Zhang, R., Wang, L., Zhang, E., Zhou, X., and Meng, R. (2024). GP60 and SPARC as albumin receptors: Key targeted sites for the delivery of antitumor drugs. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1329636"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-based delivery systems: Recent advances, challenges, and opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J. Control Release"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31602","DOI":"10.1038\/s41598-025-16848-y","article-title":"Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks","volume":"15","author":"Qin","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-025-07626-5","article-title":"A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer","volume":"211","author":"Chen","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101223","DOI":"10.1016\/j.drup.2025.101223","article-title":"Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies","volume":"81","author":"Beretta","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e010960","DOI":"10.1136\/jitc-2024-010960","article-title":"Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy","volume":"13","author":"Kalinski","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kuznetsova, A.V., Glukhova, X.A., Beletsky, I.P., and Ivanov, A.A. (2025). NK cell activity in the tumor microenvironment. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1609479"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41388-024-03211-0","article-title":"Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity","volume":"44","author":"Escoto","year":"2025","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bi, X., Wang, Y., Wang, J., and Liu, C. (2025). Machine learning for multi-target drug discovery: Challenges and opportunities in systems pharmacology. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091186"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100213","DOI":"10.1016\/j.medidd.2025.100213","article-title":"Generative AI for drug discovery and protein design: The next frontier in AI-driven molecular science","volume":"27","author":"Das","year":"2025","journal-title":"Med. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70317","DOI":"10.1002\/mco2.70317","article-title":"Applications of artificial intelligence in biotech drug discovery and product development","volume":"6","author":"Liu","year":"2025","journal-title":"MedComm"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e15701638326869","DOI":"10.2174\/0115701638326869250207060616","article-title":"In-silico approaches for drug designing technology: Bridging discovery and development","volume":"22","author":"Aminul","year":"2025","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_24","unstructured":"National Center for Biotechnology Information (NCBI) (2025, September 22). PubChem Compound Summary for CID 36314, Paclitaxel, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Paclitaxel."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_26","unstructured":"UniProt Consortium (2023). UniProt: The Universal Protein Knowledgebase in 2023. Nucleic Acids Res., 51, D523\u2013D531."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e006694","DOI":"10.1136\/jitc-2023-006694","article-title":"Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors","volume":"11","author":"Sun","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ahire, E.D., Savaliya, N., Makwana, K.V., Salave, S., Banth, M.K., Bhavsar, B., Khunt, D., and Prajapati, B.G. (2025). Protein-bound nano-injectable suspension: Unveiling the promises and challenges. Appl. Nano, 6.","DOI":"10.3390\/applnano6020009"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","article-title":"Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration","volume":"76","author":"Chen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2147\/DDDT.S200679","article-title":"Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: Determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography\u2013tandem mass spectrometry","volume":"13","author":"Li","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1021\/acsami.1c03065","article-title":"Evidence for delivery of abraxane via a denatured-albumin transport system","volume":"13","author":"Hama","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cho, H., Jeon, S.I., Ahn, C.H., Shim, M.K., and Kim, K. (2022). Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: Current understandings and clinical translation. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040728"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108522","DOI":"10.1016\/j.jbc.2025.108522","article-title":"Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides","volume":"301","author":"Petersen","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.2147\/IJN.S490400","article-title":"Unveiling the hidden risks: An update decade-long analysis of abraxane-related adverse events from the faers database","volume":"19","author":"Zhao","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Anand Raj, L.F.A., Velmurugan, K., Baskaran, S., and Namasivayam, S.K.R. (2026). Albumin Nanoparticles for Targeted Cancer Therapy: Mechanistic Insights Into Bio-Inspired Design and Clinical Translation. Biotechnol. Bioeng., 1\u201326.","DOI":"10.1002\/bit.70264"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s12325-019-01058-6","article-title":"Pharmacokinetics of total and unbound paclitaxel after administration of paclitaxel micellar or nab-paclitaxel: An open, randomized, cross-over, explorative study in breast cancer patients","volume":"36","author":"Lilienberg","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.026","article-title":"Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy","volume":"267","author":"Wang","year":"2017","journal-title":"J. Control Release"},{"key":"ref_43","unstructured":"European Medicines Agency (2024). Abraxane: EPAR\u2013Product Information, EMA. Available online: https:\/\/www.ema.europa.eu."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13578-023-01165-6","article-title":"Neurokinin-2 receptor negatively modulates substance P responses by forming complex with Neurokinin-1 receptor","volume":"13","author":"Nguyen","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.apsb.2025.03.025","article-title":"The neuroscience of cancer: Focus on neuropeptidergic systems","volume":"15","author":"Dong","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez, M.L., Rodr\u00edguez, F.D., and Cove\u00f1as, R. (2023). Peptidergic systems and cancer: Focus on tachykinin and calcitonin\/calcitonin gene-related peptide families. Cancers, 15.","DOI":"10.3390\/cancers15061694"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1756-9966-29-55","article-title":"SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D","volume":"29","author":"Huang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5577820","DOI":"10.1155\/2021\/5577820","article-title":"Prognostic significance of substance p\/Neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma","volume":"2021","author":"Mehboob","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.biopha.2018.09.013","article-title":"Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P","volume":"108","author":"Nizam","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.npep.2024.102479","article-title":"NK1 receptor blockade disrupts microtumor growth and aggregation in a three-dimensional murine breast cancer model","volume":"109","author":"Gutierrez","year":"2025","journal-title":"Neuropeptides"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5582811","DOI":"10.1155\/2022\/5582811","article-title":"A Substance P (SP)\/Neurokinin-1 receptor axis promotes perineural invasion of pancreatic cancer and is affected by lncRNA LOC389641","volume":"2022","author":"Ji","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz, M., and Rosso, M. (2025). Radiotherapy plus the neurokinin-1 receptor antagonist aprepitant: A potent therapeutic strategy for the treatment of diffuse intrinsic pontine glioma. Cancers, 17.","DOI":"10.3390\/cancers17030520"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e71148","DOI":"10.1002\/cam4.71148","article-title":"Anti-metastatic effects of aprepitant on glioblastoma cells: Targeting the substance p\/neurokinin-1 pathway","volume":"14","author":"Dikmen","year":"2025","journal-title":"Cancer Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Robinson, P., Rosso, M., and Mu\u00f1oz, M. (2023). Neurokinin-1 receptor antagonists as a potential novel therapeutic option for osteosarcoma patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062135"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Srivastava, A., Rikhari, D., Pradhan, B., Bharadwaj, K.K., Gaballo, A., Quarta, A., Jena, M., Srivastava, S., and Ragusa, A. (2022). An insight into neuropeptides inhibitors in the biology of colorectal cancer: Opportunity and translational perspectives. Appl. Sci., 12.","DOI":"10.3390\/app12188990"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.2174\/0109298673261625230924114406","article-title":"The use of SP\/neurokinin-1 as a therapeutic target in colon and rectal cancer","volume":"31","author":"Redondo","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cove\u00f1as, R., Rodr\u00edguez, F.D., and Mu\u00f1oz, M. (2024). Fighting cancer using selective antagonists targeting the substance p\/neurokinin-1 receptor system. Interdisciplinary Cancer Research, Springer.","DOI":"10.1007\/16833_2024_286"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"125965","DOI":"10.1016\/j.ijpharm.2025.125965","article-title":"Amphiphilic albumin-based nanoparticles designed for the efficient delivery of taxanes","volume":"682","author":"Xiong","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151075","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","year":"2020","journal-title":"Eur. J. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41421-022-00437-8","article-title":"Structural insights into the activation of neurokinin 2 receptor by neurokinin A","volume":"8","author":"Sun","year":"2022","journal-title":"Cell Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41392-024-02100-y","article-title":"Beyond incretins: Targeting neurokinin receptors for obesity treatment","volume":"10","author":"Thor","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41421-023-00564-w","article-title":"Structural insights into neurokinin 3 receptor activation by endogenous and analogue peptide agonists","volume":"9","author":"Sun","year":"2023","journal-title":"Cell Discov."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shoaib, T.H., Ibraheem, W., Abdelrahman, M., Osman, W., Sherif, A.E., Ashour, A., Ibrahim, S.R.M., Ghazawi, K.F., Miski, S.F., and Almadani, S.A. (2023). Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0289887"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bono, A., La Monica, G., Alamia, F., Mingoia, F., Gentile, C., Peri, D., Lauria, A., and Martorana, A. (2023). In silico mixed ligand\/structure-based design of new CDK-1\/PARP-1 dual inhibitors as anti-breast cancer agents. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813769"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.saa.2013.11.028","article-title":"Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer","volume":"122","author":"Bayrak","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/0250-474X.180254","article-title":"Molecular and computational studies on apoptotic pathway regulator, Bcl-2 gene from breast cancer cell line MCF-7","volume":"78","author":"Tiwari","year":"2016","journal-title":"Indian. J. Pharm. Sci."}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/13\/8\/953\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:13:44Z","timestamp":1787584424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/13\/8\/953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["bioengineering13080953"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering13080953","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}